These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 4278421)

  • 1. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R; Colebatch JH; Gordon P; Ekert H
    Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 3. [Desferrioxamine in thalassemia].
    Biener R; Freundlich E; Rachmilewitz E
    Harefuah; 1983 May; 104(10):438-40. PubMed ID: 6629159
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 6. Urinary iron excretion in thalassaemia after desferrioxamine administration.
    Seshadri R; Colebatch JH; Fisher R
    Arch Dis Child; 1974 Mar; 49(3):195-9. PubMed ID: 4825624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 8. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N; Ullrich D; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M; Karpatkin M; Hart D; Seaman C; Vora SK; Henry WL; Piomelli S
    J Pediatr; 1978 Apr; 92(4):653-8. PubMed ID: 633033
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E; Bianco I; Masi M
    Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 18. Subcutaneous desferrioxamine in homozygous beta-thalassaemia.
    Silvestroni E; Bianco I; Graziani B; Carboni C; Costantini S
    Lancet; 1978 Nov; 2(8100):1149-50. PubMed ID: 82705
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
    Wöhler F
    Blut; 1967 Apr; 15(1):33-42. PubMed ID: 6025965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.